Prostate cancer is the most common solid-organ cancer affecting the male population.
Men with metastatic prostate cancer treated with androgen ablation therapy often respond rapidly, with improvement in bone pain and decreases in serum prostate-specific antigen. However, almost all patients progress to the castrate-resistant state and until recently chemotherapy was the only treatment available with proven survival benefit. Abiraterone is a new class of anti-androgen with proven survival benefit post-chemotherapy. In this review we discuss the characteristics of abiraterone and the clinical trials that led to its approval for the treatment of patients with prostate cancer.
Rawlinson A, Mohammed A, Beatty J, Bell R, Miller M. Are you the author?
Department of Urology, Northampton General Hospital, Northampton, UK.
Reference: Expert Rev Anticancer Ther. 2012 Apr;12(4):429-37.